Turning Point Benefit Group’s Vaxcyte PCVX Stock Holding History

Turning Point Benefit Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20	Closed	-$922	–	588
2025 Q4	$922	Buy	+20	New	+$895	﹤0.01%	570

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Turning Point Benefit Group's PCVX Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 20 shares — an estimated $922 sold.

Turning Point Benefit Group first reported a position in PCVX in Q4 2025 and held it in 1 quarter. The position peaked at $922 in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Turning Point Benefit Group reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
Turning Point Benefit Group sold 20 Vaxcyte shares in Q1 2026, an estimated $922.
Turning Point Benefit Group first reported a position in Vaxcyte in Q4 2025 and held it in 1 quarter.
Turning Point Benefit Group's Vaxcyte position peaked at $922 in Q4 2025.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.